Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lexicon Pharmaceuticals, Inc.

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Appoints Scott Coiante as Chief Financial Officer
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Pharmaceuticals to Participate in December Investor Conferences
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Lexicon Appoints Ivan H. Cheung to Board of Directors
From Lexicon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers LXRX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.